Compare CFND & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFND | VNRX |
|---|---|---|
| Founded | N/A | N/A |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.5M | 38.2M |
| IPO Year | 2025 | N/A |
| Metric | CFND | VNRX |
|---|---|---|
| Price | $5.05 | $0.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.17 |
| AVG Volume (30 Days) | N/A | ★ 2.8M |
| Earning Date | N/A | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,472,007.00 |
| Revenue This Year | N/A | $55.33 |
| Revenue Next Year | N/A | $493.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.48 |
| 52 Week Low | N/A | $0.27 |
| 52 Week High | N/A | $0.94 |
| Indicator | CFND | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 31.94 |
| Support Level | N/A | $0.28 |
| Resistance Level | N/A | $0.31 |
| Average True Range (ATR) | 0.00 | 0.03 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 3.40 |
C1 Fund Inc is a non-diversified, closed-end management investment company designed to give investors access to the private digital asset ecosystem. Its investment objective is to maximize its portfolio's total return. The fund targets a handpicked portfolio of the late-stage private companies driving the future of digital asset services and technology. It offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the private companies with the safeguards of a NYSE listed fund that is regulated and liquid.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.